Tricyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos Patents (Class 514/220)
  • Patent number: 11007189
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 18, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10988459
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: April 27, 2021
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Craig Stivala, Huifen Chen, Guiling Zhao
  • Patent number: 10966999
    Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 6, 2021
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • Patent number: 10966974
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 6, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10945973
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: March 16, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10925967
    Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 23, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Dennis Dobrovolsky, Hai-Tsang Huang
  • Patent number: 10913752
    Abstract: The present invention provides bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V), and (VI). Some bromdomain-containing proteins (e.g., BRD4) have a tandem bromodomain primary structure comprising more than one bromodomain binding site (e.g., BRD4 comprises BD1 and BD2). Bivalent inhibitors of BET bromodomains provided herein can target bromodomains through advantageous multivalent interactions, and can therefore can be to treat diseases or conditions associated with bromodomain-containing proteins. The present also provides pharmaceutical compositions and kits comprising the inventive compounds, as well as methods of using the inventive compounds.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 9, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Jun Qi, Minoru Tanaka, Justin M. Roberts
  • Patent number: 10894046
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: January 19, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10894047
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: January 19, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10874663
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: December 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10874665
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10874664
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10864209
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: December 15, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10836764
    Abstract: The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: November 17, 2020
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Graeme Semple, Albert S. Ren, Thomas O. Schrader, Michelle Kasem, Xiuwen Zhu
  • Patent number: 10807973
    Abstract: New compounds and a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, including administering compound of the formula (I) or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is a 5-oxazolyl residue or a pyridine-4-yl residue, R1 is selected from the group consisting of fluoro, chloro and methoxy; B is selected from the group consisting of a residue of formula (II), (III) and (IV) wherein, “*” denotes the point of attachment to the remainder of the molecule, and R2, R2?, R2?, R3, R3?, R3?, R4, R4?, R4?, R5, R5? and R5? are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 4 carbon atoms, trifluoromethyl, 2,2,2-trifluoroethyl, methylsulfanyl, ethylsulfanyl, methylsulfonyl, ethylsulfonyl, difluoromethoxy, trifluoromethoxy, fluoro, bromo, chloro, methoxy, ethoxy, propoxy, butoxy, hydroxy and amino.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: October 20, 2020
    Assignee: ENDOGENA THERAPEUTICS, INC.
    Inventors: Matthias Steger, Alex Mueller, Bernhard Fasching, Daphna Mokady
  • Patent number: 10799511
    Abstract: The present invention includes compounds, compositions and methods for reducing or ameliorating mortality and/or morbidity due to chlorine inhalation.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: October 13, 2020
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Livia A. Veress
  • Patent number: 10786498
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, said combination having a synergistic effect in the treatment of pain.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: September 29, 2020
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Beatrice Garrone, Lucia Durando, Fabrizio Calisti
  • Patent number: 10772894
    Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 15, 2020
    Assignee: Resverlogix Corp.
    Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R. A. Halliday, Henrik C. Hansen
  • Patent number: 10722479
    Abstract: Described are dimethoxyphenyl inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: July 28, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Patent number: 10716792
    Abstract: The present inventive concept describes a method for treating the neurovascular disruption underlying Epileptic Seizures and other traits of Epilepsy and Infantile Spasms by improving the neurophysiological environment and then enabling by sustained sedation a biomechanism of glial cells for neuronal repairs.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: July 21, 2020
    Inventors: Gary Aaron Howard, Debora Zucco Sassi Yonezawa Siviglia
  • Patent number: 10695355
    Abstract: Described herein are methods for the treatment of a human subject who has had a stroke by administering to the subject a pharmaceutical composition including an antagonist of the P2X4 receptor. The antagonist of the P2X4 receptor can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 30, 2020
    Assignees: UNIVERSITY OF CONNECTICUT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Bruce Liang, Rajkumar Verma, Kenneth A. Jacobson
  • Patent number: 10688047
    Abstract: Physically and chemically stable oral liquid formulations of Givinostat (Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride) are disclosed, together with methods for the preparation thereof. Such oral formulations are in the form of aqueous suspensions and contain Givinostat and/or pharmaceutically acceptable salts and/or derivatives thereof, at least a wetting agent and/or at least a density-imparting agent. Such formulations are suitable for oral administration for systemic therapeutic action.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: June 23, 2020
    Assignee: ITALFARMACO SPA
    Inventors: Giuseppe Colombo, Roberta Artico, Paolo Mascagni, Maria Valmen Monzani, Silvia Puccianti
  • Patent number: 10676484
    Abstract: The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: June 9, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Cold Spring Harbor Institute
    Inventors: James Elliott Bradner, Johannes Zuber, Junwei Shi, Christopher R. Vakoc, Scott W. Lowe, Constantine S. Mitsiades
  • Patent number: 10675258
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 9, 2020
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Clark P. Allphin, Michael DesJardin
  • Patent number: 10668030
    Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: June 2, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Linda P. Dwoskin, Peter Anthony Crooks, Guangrong Zheng, Justin R. Nickell, Zheng Cao, Na-Ra Lee
  • Patent number: 10646443
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 12, 2020
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • Patent number: 10640507
    Abstract: The invention relates to pyrrolobenzodiazepines compounds (PBDs) and to pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular, to treat bacterial infections.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 5, 2020
    Assignees: King's College London, Secretary of State for Health and Social Care
    Inventors: Khondaker Mirazur Rahman, John Mark Sutton, Pietro Picconi
  • Patent number: 10526294
    Abstract: The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 7, 2020
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Joshua D. Thomas, Mao Yin, Aleksandr V. Yurkovetskiy, Patrick R. Conlon, Ahmed Hilmy, Eugene W. Kelleher, Timothy B. Lowinger, Cheri A. Stevenson, Shuyi Tang
  • Patent number: 10512643
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 24, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10493045
    Abstract: A method for treating alcohol dependence or alcohol abuse in a subject comprising administering to the subject a composition comprising an effective amount of memantine, wherein the effective amount of memantine is 2-4.7 mg/day. Low dose of memantine having anti-inflammatory and neurotrophic effect is able to reduce alcohol use.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 3, 2019
    Inventor: Ru-Band Lu
  • Patent number: 10463638
    Abstract: Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a N-methyl-D-aspartate (NMDA) receptor antagonist into the chamber. The methods may comprise respectively depositing a muscle relaxant, a local anesthetic into the chamber, depositing an anticonvulsant into the chamber, depositing an antidepressant into the chamber, and depositing a calcium channel blocking agent into the chamber. The methods may comprise milling the NSAID compound, the NMDA receptor antagonist, the muscle relaxant, the local anesthetic, the anticonvulsant, the antidepressant, and the calcium channel blocking agent into a powder. The methods may comprise adding a solvent with the powder and mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution and mixing the base cream and the solution to form the formulation.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: November 5, 2019
    Assignee: SYNERGISTIC THERAPEUTICS, LLC
    Inventors: Anthony H. Salce, Jr., William F. Greenwood, Shivsankar Misir
  • Patent number: 10450319
    Abstract: The present invention relates to a salt form of a benzodiazepine derivative, in particular crystalline solid state forms, to pharmaceutical compositions comprising the same and to its use in therapy.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Gossett Augustus Campbell, Asa Elisabeth Gladwin
  • Patent number: 10442819
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 15, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis, Sara Esposite, Qingmei Hong, Chunhui Huang, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Ryan D. Otte, Dann L. Parker, Jr., Michael Reutershan, Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Feroze Ujjainwalla, Catherine White, Zhicai Wu, Yang Yu, Kake Zhao, Craig Gibeau, Tesfaye Biftu, Purakkattle Biju, Lei Chen, Joshua Close, Peter H. Fuller, Xianhai Huang, Min K. Park, Valdimir Simov, David J. Witter, Hongjun Zhang
  • Patent number: 10421763
    Abstract: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: September 24, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Patent number: 10399972
    Abstract: The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David J. Witter, Tesfaye Biftu, Purakkattle Biju, Stephane L. Bogen, Qingmei Hong, Chunhui Huang, Xianhai Huang, Bing Li, Min K. Park, David L. Sloman
  • Patent number: 10369143
    Abstract: Provided herein is a method of treating a central nervous system disorder in a patient in need thereof, wherein the central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia. The method comprises orally administering an initial dose of between 75 mg and 300 mg xanomeline and an initial dose of between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. Provided that the patient tolerates said administration, an increased dose of trospium chloride and an increased dose of xanomeline are orally administering to the patient, wherein the increased dose of trospium chloride is greater than the initial dose of the trospium chloride, and wherein the increased dose of xanomeline is greater than the initial dose of the xanomeline.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: August 6, 2019
    Assignee: PureTech Health LLC
    Inventors: Eric Elenko, Philip E. Murray, III, Andrew C. Miller
  • Patent number: 10328076
    Abstract: The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 25, 2019
    Assignee: PHARMATHEN S.A.
    Inventor: Evangelos Karavas
  • Patent number: 10278975
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 7, 2019
    Assignee: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Patent number: 10265311
    Abstract: Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 23, 2019
    Assignee: PureTech Health LLC
    Inventors: Eric Elenko, Andrew C. Miller, Philip E. Murray, III
  • Patent number: 10259815
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 16, 2019
    Assignee: UWM Research Foundation, Inc.
    Inventors: James Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • Patent number: 10251879
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 9, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10239888
    Abstract: The present application provides bifunctional compounds of Formula I or II: or an enantiomer, diastereomer, or stereoisomer, or a pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds of Formula (I) or (II) that link a mutant cereblon-binding moiety to a ligand that is capable of binding to a targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof. The present application also relates to polynucleotides or polypeptides of a mutant cereblon and methods of use thereof.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 26, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Mette Ishoey, Dennis Buckley, Joshiawa Paulk, Marc Andrew Cohen, Rhamy Zeid
  • Patent number: 10239834
    Abstract: The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria. The photosensitive compounds can also be used to inhibit the proliferation of cancer cells.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: March 26, 2019
    Assignee: NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION
    Inventors: Snezna Rogelj, Liliya Frolova, Alexander Kornienko, Leslie D. Edwards, Cody Champion, Kailee Zingler, Danielle Nicole Turner
  • Patent number: 10238620
    Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: March 26, 2019
    Assignees: Pernix Sleep, Inc., ProCom One, Inc.
    Inventors: Roberta L. Rogowski, Susan E. Dubé, Philip Jochelson, Neil B. Kavey
  • Patent number: 10238651
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: March 26, 2019
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Magali B. Hickey, Jennifer Vandiver
  • Patent number: 10208042
    Abstract: The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e] [1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: February 19, 2019
    Assignee: Nanjing TransThera Biosciences Co. Ltd.
    Inventor: Frank Wu
  • Patent number: 10188657
    Abstract: Provided are articles of manufacture, compositions and methods for prophylaxis and/or therapy for disorders involving dizziness and/or vertigo. The articles of manufacture and compositions contain lamotrigen and/or bupropion. The compositions include pharmaceutical compositions which are intended to alleviate dizziness and/or vertigo. In certain aspects the disclosure includes articles of manufacture and kits which include printed material which provides an indication that the articles or compositions are intended to be used for prophylaxis and/or therapy of Meniere's Disease or a symptom thereof.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: January 29, 2019
    Inventor: Lixin Zhang
  • Patent number: 10143695
    Abstract: The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: December 4, 2018
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Mao Yin, Joshua D. Thomas, Aleksandr V. Yurkovetskiy, Patrick R. Conlon, Bingfan Du, Eugene W. Kelleher, Timothy B. Lowinger, Shuyi Tang
  • Patent number: 10143676
    Abstract: The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 4, 2018
    Assignees: Pernix Sleep, Inc., ProCom One, Inc.
    Inventors: Susan E. Dubé, Neil B. Kavey
  • Patent number: 10124009
    Abstract: The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using the compounds and pharmaceutical compositions described.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 13, 2018
    Assignee: Tensha Therapeutics, Inc.
    Inventors: Steven B. Landau, Michael Kagey